Hiroyuki Shibata
Graduate School of Medicine, Hondo 1-1-1, Akita
Japan
Case Report
Possibility of TAS-102 as an Early Line Therapy Against Advanced Colorectal Cancer
Author(s): Taichi Yoshida, Koji Fukuda, Daiki Taguchi, Kazuhiro Shimazu, Masahiro Inoue and Hiroyuki ShibataTaichi Yoshida, Koji Fukuda, Daiki Taguchi, Kazuhiro Shimazu, Masahiro Inoue and Hiroyuki Shibata
Introduction: New drugs have improved the outcome of metastatic colorectal cancer treatment. In Japan, more than 10 agents with at least seven different mechanisms such as 5-fluorouracil (5-FU), irinotecan (IRI), oxaliplatin, angiogenesis inhibitors, anti-epidermal growth factor receptor antibodies, regrafenib, and TAS-102, have been approved. With the increase in the number of alternatives, the importance of choosing the agents increases. To suppress the toxicities of agents is also necessary. To increase the quality of life of the patients should be taken into consideration for their longer survival. TAS-102 has proved to be an effective and safe agent for the 3rd or 4th lines of advanced colorectal cancer.
Presentation of case: We report a case of a patient who had suffered severe adverse events from standard firstline chemotherapy with 5.. View More»